Abstract
Application of viral vectors derived from human viruses to mediate immune response in animals and humans has been greatly hampered by the problems associated with pre-existing immunity and associated toxicities. Among few non-human viral vectors, baculovirus has now evolved as a novel tool for vaccine vector development. With broad tissue tropism and expanded bio-safety profile suitably supplemented with intrinsic immunostimulatory properties, baculovirus has now attained a niche position in the arena of vaccine development. Recombinant envelope-modified baculovirus equipped with novel shuttle promoters for in vivo transduction has shown promising results in several animal models. Baculovirus mediated induction of systemic and mucosal immune responses through intranasal or oral administration has now opened an entirely new way for the development of new generation vaccines. Gaining additional insight into the baculovirus biology and its interaction with non-native hosts will certainly promote this human-friendly virus as a potential vector for clinical applications.
Keywords: Non-human viral vector, recombinant baculovirus, gene-delivery, vaccine, innate immunity, infectious diseases
Current Gene Therapy
Title: Baculovirus as Vaccine Vectors
Volume: 10 Issue: 3
Author(s): Selvaraj Madhan, Mookkan Prabakaran and Jimmy Kwang
Affiliation:
Keywords: Non-human viral vector, recombinant baculovirus, gene-delivery, vaccine, innate immunity, infectious diseases
Abstract: Application of viral vectors derived from human viruses to mediate immune response in animals and humans has been greatly hampered by the problems associated with pre-existing immunity and associated toxicities. Among few non-human viral vectors, baculovirus has now evolved as a novel tool for vaccine vector development. With broad tissue tropism and expanded bio-safety profile suitably supplemented with intrinsic immunostimulatory properties, baculovirus has now attained a niche position in the arena of vaccine development. Recombinant envelope-modified baculovirus equipped with novel shuttle promoters for in vivo transduction has shown promising results in several animal models. Baculovirus mediated induction of systemic and mucosal immune responses through intranasal or oral administration has now opened an entirely new way for the development of new generation vaccines. Gaining additional insight into the baculovirus biology and its interaction with non-native hosts will certainly promote this human-friendly virus as a potential vector for clinical applications.
Export Options
About this article
Cite this article as:
Madhan Selvaraj, Prabakaran Mookkan and Kwang Jimmy, Baculovirus as Vaccine Vectors, Current Gene Therapy 2010; 10 (3) . https://dx.doi.org/10.2174/156652310791321233
DOI https://dx.doi.org/10.2174/156652310791321233 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Osteoblast Differentiation and Control by Vitamin D and Vitamin D Metabolites
Current Pharmaceutical Design Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Current Gene Therapy The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets Aspartic Proteases of Human Pathogenic Fungi are Prospective Targets for the Generation of Novel and Effective Antifungal Inhibitors
Current Enzyme Inhibition Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications
Current Cancer Therapy Reviews Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers
Current Cancer Drug Targets Viruses and Oral Cancer: Crossreactivity as a Potential Link
Anti-Cancer Agents in Medicinal Chemistry The Chemical Methods of Disulfide Bond Formation and Their Applications to Drug Conjugates
Current Organic Chemistry The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry HIV-1 Integrase Binding to its Cellular Partners: A Perspective from Computational Biology
Current Pharmaceutical Design Cancer Genetics and Drug Discovery in Mice
Letters in Drug Design & Discovery Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging